French Alternative Energies And Atomic Energy Commision
- Address
- lock Available on a paid plan
Psychiatry and Psychology
At Service Hospitalier Frédéric Joliot - CEA, clinical research in mental disorders focuses on severe major depressive disorder and schizophrenia, with studies designed to better understand symptoms and brain changes linked to treatment response and disease biology.
- Testing a new approach to improve depressive symptoms in hospitalized patients with severe depression
- Exploring brain-based markers that may track recovery and treatment effects in depression
- Studying neuroinflammation and genetic factors in schizophrenia
This research combines psychiatry with advanced PET imaging and other diagnostic tools to support more precise diagnosis and treatment monitoring.
Nervous System Diseases
The site conducts research on several nervous system diseases, including Alzheimer's disease, multiple sclerosis, Huntington's disease, and epilepsy, with a strong emphasis on understanding how these conditions progress in the brain.
- Mapping tau-related brain changes in Alzheimer's pathology
- Measuring inflammatory activity in multiple sclerosis
- Identifying biomarkers that may predict Huntington's disease progression
- Improving seizure focus localization in drug-resistant epilepsy
These studies aim to improve diagnosis, guide care decisions, and support earlier detection of disease-related changes through neuroimaging and biomarker research.
Neoplasms and Oncology Imaging
Research in neoplasms at this French Alternative Energies And Atomic Energy Commision site includes imaging-based studies in patients with polymetastatic solid cancers, reflecting a broader effort to understand how cancer behaves and how it responds to treatment.
- Studying imaging signals linked to tumor activity
- Assessing how advanced scans can support cancer evaluation
- Exploring ways to improve monitoring of disease spread and treatment impact
The work centers on diagnostic techniques and investigative imaging that may strengthen cancer assessment in clinical practice.
Analytical, Diagnostic and Therapeutic Techniques and Equipment
A major part of the research program at Service Hospitalier Frédéric Joliot - CEA is dedicated to analytical and diagnostic techniques, especially advanced brain imaging used to study disease mechanisms and treatment effects across neurological and psychiatric conditions.
- Evaluating PET and MRI methods for better disease detection
- Using imaging to compare treatment effects and biological changes
- Developing tools that may improve localization, monitoring, and prognosis
This area supports research across anesthesia and analgesia, investigative techniques, and broader clinical imaging applications aimed at making diagnosis and follow-up more accurate.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 3 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in French Alternative Energies And Atomic Energy Commision
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of [18F]MNI-659 as a Biomarker for Monitoring Disease Progression in Symptomatic and Pre-symptomatic Huntington's Disease Patients | Assistance Publique Hopitaux De Paris | Phase III | Recruiting | Mar 2024 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 2-[2-[3-[4-(2-(18F)FLUORANYLETHOXY)PHENYL]-7-METHYL-4-OXOQUINAZOLIN-2-YL]ETHYL]-4-PROPAN-2-YLOXYISOINDOLE-1,3-DIONE | 1 | Unknown | 2024-03-21 | 2024-03-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.